David Fairley and Alan Williams accept invitation to join Offspring Biosciences Board of Directors

Södertälje, January 21, 2021 -- Offspring Biosciences AB, a leading global provider of advanced molecular pathology services, announced that its Board of Directors has elected David Fairley and Alan Williams as Non-Executive Directors effective today.

David Fairley, currently Chief Executive Officer of Histopath Consulting Ltd, and previously Managing Director and owner of Histologix Ltd, which he took from startup through to sale, has been involved in a range of global research and regulatory projects including, but not limited to, immuno-oncology, in situ hybridization, antibody multiplexing, immunohistochemistry assay validation, image analysis and biosimilars, and as a result is able to advise on a range of technical issues. He has a wealth of knowledge and experience gained from within the contract research regulatory environment over many years and has been technically and commercially responsible for developing and running specialised histology studies for the pharmaceutical and biotechnology industry.

Commenting on his acceptance, David said, "I am pleased to announce I have accepted this invitation to join the board of OffSpring Biosciences as a Non-Executive Director with a role to provide strategic advice on testing services, the introduction of international quality standards, in addition to identifying new commercial avenues and opportunities for growth".

Alan Williams is Chief Executive Officer of Talk Biotech Ltd, where he provides a range of life sciences research products and services, and commercial consulting services including support for technology and biotechnology startups, small to medium enterprises and university spinouts. He has over 20 years of experience in the life sciences industry, including working within an FDA audited GLP-compliant lab, several commercial roles for a blue-chip global technology company, and senior commercial roles at contract research organizations.

Of his acceptance, Alan commented, "Offspring Biosciences is an innovative provider of advanced contract research services, delivering highly reliable and informative data for critical project decisions. I am honoured and delighted for this opportunity to join the company's Board and help contribute towards the success of Offspring Biosciences".

About Offspring Biosciences AB
Offspring Biosciences, which emerged from AstraZeneca’s Södertälje site for Research and Development, is an advanced CRO partner to customers within the biotechnology and pharmaceutical industry, delivering data to support decision making for successful and cost-effective development of novel treatments to advance human health. For more information, please visit our website www.offspringbiosciences.se

Offspring Biosciences Sweden AB
Biovation Park
Forskargatan 20J
Södertälje
Sweden
Phone: +46(0)8 400 112 30
E-mail: contact@offspringbiosciences.com

Press Contact for Offspring Biosciences
Anders Dahlstrand, CEO
anders.dahlstrand@offspringbiosciences.com

Offspring Biosciences provides advanced contract research services to customers primarily within the pharmaceutical and biotechnology industry. We deliver data which supports decision making for successful and more cost-effective development of novel treatments of human diseases. The information targets key questions in pharmaceutical drug development such as the relevancy of the chosen drug targets, the drug binding properties, the effectiveness of the drug in preclinical treatment studies of mechanistic and pathology-associated biomarkers as well as safety liabilities and manifestations. In addition, we facilitate our customer’s translational research with comparative analyses between the human disease state and the corresponding preclinical models in animals and can provide support for development of ligands for PET imaging.

This release was published on openPR.